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Abstract
Background: The major toxic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) appear to result from 
dysregulation of mRNA levels mediated by the aryl hydrocarbon receptor (AHR). Dioxin-like chemicals alter expression 
of numerous genes in liver, but it remains unknown which lie in pathways leading to major toxicities such as 
hepatotoxicity, wasting and lethality. To identify genes involved in these responses we exploited a rat genetic model. 
Rats expressing an AHR splice-variant lacking a portion of the transactivation domain are highly resistant to dioxin-
induced toxicities. We examined changes in hepatic mRNA abundances 19 hours after TCDD treatment in two dioxin-
resistant rat strains/lines and two dioxin-sensitive rat strains/lines.
Results: Resistant rat strains/lines exhibited fewer transcriptional changes in response to TCDD than did rats with 
wildtype AHR. However, well-known AHR-regulated and dioxin-inducible genes such as CYP1A1, CYP1A2, and CYP1B1 
remained fully responsive to TCDD in all strains/lines. Pathway analysis indicated that the genes which respond 
differently to TCDD between sensitive and resistant rats are mainly involved in lipid metabolism, cellular membrane 
function and energy metabolism. These pathways previously have been shown to respond differently to dioxin 
treatment in dioxin-sensitive versus dioxin-resistant rats at a biochemical level and in the differential phenotype of 
toxicologic responses.
Conclusion: The transactivation-domain deletion in dioxin-resistant rats does not abolish global AHR transactivational 
activity but selectively interferes with expression of subsets of genes that are candidates to mediate or protect from 
major dioxin toxicities such as hepatotoxicity, wasting and death.
Background
Dioxin-like chemicals are exceptionally toxic to a wide
variety of birds, fish and mammals including, perhaps,
humans. However, susceptibility to dioxin toxicity varies
widely among different animal species and between
genetic types within a species. Extensive evidence dem-
onstrates that virtually all toxic effects of TCDD and
related dioxin-like compounds are mediated by a ligand-
dependent transcription factor, the aryl hydrocarbon
receptor (AHR) (reviewed in: [1]). Exposure to dioxins
results in major toxicities, including thymic atrophy,
teratogenesis, hepatotoxicity, wasting syndrome and
death. These toxicities are dependent on both the AHR
and its dimerization partner, the aryl hydrocarbon recep-
tor nuclear translocator (ARNT), and require that the
AHR have functional structures for nuclear translocation
and DNA binding [2-6].
Dioxin binding converts the AHR into an activated
ligand:AHR:ARNT complex that regulates transcription
either by binding directly to AHRE-I motifs (also known
as DREs or XREs) [7-10] or indirectly to AHRE-II motifs
[11,12]. Dioxin toxicities appear to arise from AHR-medi-
ated dysregulation of specific genes [4,13]. Microarray
technologies have accelerated identification of genes that
depend on the AHR for constitutive expression or for
response to TCDD in vivo [14-23], but the key genes
whose dysregulation by dioxin leads to most toxicities
remain unknown.
The Han/Wistar(Kuopio) (H/W) rat is an excellent
model organism to identify specific AHR-regulated genes
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whose dysregulation by dioxin may lead to major toxici-
ties. H/W rats are extraordinarily resistant to acute
lethality from TCDD, with an LD50 three orders of magni-
tude higher than for sensitive Long-Evans(Turku/AB) rats
(L-E) [24]. Resistance in H/W rats is associated with a
point m utation that leads to expression of an aberrant
AHR protein missing 38 or 43 amino acids from its trans-
activation domain (TAD) [25-27]. We recently demon-
strated, using transgenic mouse models, that it is the
AHR variant with 38 amino acids deleted that is responsi-
ble for dioxin resistance [28]. Importantly, this AHR vari-
ant is the predominantly-expressed form in the dioxin-
resistant H/W rat [27]. Further, dioxin resistance in rats
segregates genetically with the AHR locus and is a domi-
nant trait [24,26]. Multi-generational crosses of L-E and
H/W rats and selection for susceptibility or resistance to
dioxin lethality [26] produced two rat lines: Line-A (LnA)
and Line-C (LnC). LnA rats harbour the variant AHR and
are dioxin-resistant; LnC rats have the wildtype AHR and
are dioxin-sensitive. We postulate that the partial dele-
tion of AHR transactivation domain alters toxic
responses either by preventing changes in mRNA levels
of genes in pro-death pathways or by enhancing
responses of genes in pro-survival pathways.
Our strategy for identifying pro-survival or pro-death
genes is to contrast changes in mRNA expression profiles
following TCDD exposure of dioxin-sensitive and dioxin-
resistant rats [13]. To reduce the influence of strain-spe-
cific changes not associated with dioxin toxicities, we
profiled 4 strains/lines of rats: H/W and LnA which con-
stitute the "resistant collective" and L-E and LnC which
constitute the "sensitive collective".
We focused on hepatic mRNA levels because liver dis-
plays a broad spectrum of mRNAs that are responsive to
dioxins and/or to AHR genotype [20] and because liver is
a prime site of dioxin toxicity, displaying many pheno-
typic differences between sensitive and resistant rats [29].
We chose a dose of 100 μg/kg TCDD, which produces
hepatotoxicity, wasting and death in sensitive rats but no
deaths in resistant rats. We previously conducted a
smaller-scale transcriptomic study in sensitive versus
resistant rats on membrane arrays and using cross-spe-
cies hybridization to cDNA arrays [30]. Here, we greatly
extend those prior studies by assessing transcriptome-
wide responses to TCDD which were further validated
via real-time RT-PCR. We identify specific biological
processes perturbed by TCDD exposure.
Our analysis paints a new picture of dioxin-induced
expression changes. Hundreds of genes exhibit responses
to TCDD that are specific to individual strains or lines.
Our genetic model diminishes this background noise and
identifies a small number of genes associated with hepa-
totoxicity, wasting and death. Genes differentially-
expressed between sensitive and resistant strains show
functional homogeneity: dioxin-lethality may be associ-
ated with broad dysregulation of entire pathways, not just
single genes.
Results
To determine the effect of TCDD on mRNA abundances
in dioxin-sensitive rats versus dioxin-resistant rats we
studied four rat strains/lines at 19 hours after oral admin-
istration of TCDD (Figure 1) using Affymetrix RAE230A
microarrays. A list of all genes and their responses to
TCDD in the four rat strains/lines is given in Additional
File 1.
Global differences in mRNA abundance
The total number of genes affected by TCDD varied
across rat strains/lines in a manner independent of the
statistical threshold (Figure 2A). More genes were
affected by TCDD in dioxin-sensitive rats than in dioxin-
resistant rats: across all four strains/lines, the order of the
number of transcriptional alterations was: L-E > LnC >
LnA > H/W. Overall, it appears that the deletion in the
AHR transactivation domain reduces the number of
genes altered but does not ablate the transcriptional
response to TCDD.
Unsupervised clustering analysis (Figure 2B) using all
non-constant genes (variance > 0.01) revealed the stron-
gest trend in the dataset was the distinction between
TCDD-treated (red annotation bars) and vehicle-treated
(white annotation bars) animals. The co-clustering of the
two F2 crosses (LnA, dark blue; LnC, light blue) may indi-
cate that their common parentage is a stronger determi-
Figure 1 Experimental Design. A two-factor design was used to as-
sess the effects of strain/line (L-E, LnC, LnA and H/W) and TCDD-expo-
sure (control or 19-hour exposure to 100 μg/kg TCDD). In total 32 
mRNA profiles were assessed by individual RAE230A microarrays; four 
separate animals were profiled for each of the eight separate experi-
mental conditions.Moffat et al. BMC Genomics 2010, 11:263
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nant of their transcriptional profiles than is their
sensitivity or resistance to TCDD toxicity. Further, this
suggests that number of genes causally related to the
hepatotoxicity (and possibly acute lethality) of TCDD is
small compared with all other changes caused by TCDD
in hepatic gene expression.
The extent of the overlap in transcriptional responses
to TCDD among sensitive and resistant rat strains/lines
was visualized using a two-way table (Table 1) and Venn
diagrams (Figure 3). Of the 8605 genes interrogated, 452
(5.3%) responded in at least one strain or line at a 1%
false-discovery rate; 8153 genes did not respond to
TCDD in any strain/line (Table 1). Of the 452 responsive
genes only 144 (31.9%) were altered in more than one
strain/line. Only 25 genes responded in all strains/lines,
of which 20 were induced while only 5 were genes
repressed. This direction of response is concordant with
our previous finding that 70% of genes altered in com-
mon by TCDD in both mouse and rat are up-regulated
[23].
The sensitive collective exhibited a greater number of
responsive genes (412) and a greater overlap of these
genes among strains/lines within the collective (Figure
3A) than did the resistant collective (138 responsive
genes; Figure 3B). However, the proportion of TCDD-
responsive genes that overlapped within each collective
to the total genes on the array that responded to TCDD in
that collective did not differ between collectives (22.5% in
the resistant vs. 26.2% in the sensitive collective, p = 0.44;
proportion test).
Classification of Type-I vs. Type-II responses to TCDD
Identifying which of the 452 TCDD-responsive genes are
most likely to be involved in major dioxin toxicities is
challenging; we therefore exploited our genetic model.
Each TCDD-responsive gene was classified according to
the Type-I/Type-II TCDD response scheme previously
developed for toxic endpoints [31].
Type-I responses to TCDD are those that are similar
between dioxin-sensitive rat strains/lines and dioxin-
resistant rat strains/lines. We considered genes that
exhibited a statistically significant response to TCDD in
all four strains/lines to be Type-I genes. By this definition
25 genes were classified as Type-I (Figure 3C; Score ± 4 in
Table 1). These Type-I genes include well-known (Table
2) as well as novel TCDD-responsive genes (Additional
File 1). The vast majority of Type-I genes (20/25) were
up-regulated by TCDD (score +4 in Table 1). For some
Type-I genes the magnitude of induction was very large,
including ~90-fold induction of CYP1A1  mRNA and
~75-fold induction of ALDH3A1 mRNA.
Type-II responses to TCDD are those that differ
between dioxin-sensitive rats and dioxin-resistant rats.
Genes that responded to TCDD exposure in a statistically
significant manner in both members of one collective but
neither of the strains/lines in the other collective are clas-
sified as Type-II genes. By this classification, 46 genes
exhibited Type-II responses (Figure 3C; Score ± 2 & 0 in
both ways in Table 1). Of these, only three were altered in
resistant rats but not in sensitive rats (Il1r1, Phyh, Hacl1).
The remaining 43 genes were specifically altered only in
dioxin-sensitive rats. In contrast to the 80% upregulation
of Type-I genes, 61% (28/46) of Type-II genes were down-
regulated by TCDD.
Figure 2 Global comparison of expression profiles between rat 
strains/lines. (A) The total number of genes affected by TCDD treat-
ment in each rat line or strain is compared at levels of statistical signif-
icance (adjusted p-values; -log10) ranging from 0 to 5. (B) Hierarchical 
clustering with within-row scaling of all non-constant genes (variance 
> 0.1). Within the heatmap, blue indicates genes induced (up-regulat-
ed) by TCDD; red indicates genes repressed (down-regulated) by 
TCDD. Within the annotation bars (right side of heatmap), red indicates 
which rats were exposed to TCDD and white indicates those exposed 
to corn oil vehicle. The first column of annotation bars indicates the 
strains/lines of animals profiled: yellow, L-E; light blue, LnC; green, H/W, 
dark blue, LnA. The colour-scale gives within-row-scaled expression 
values, with red hues indicating low-expression and blue hues indicat-
ing high-expression.Moffat et al. BMC Genomics 2010, 11:263
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Validation by real-time RT-PCR
The validity of our array experiments to identify effects of
TCDD on mRNA levels is supported by the facts that
well-established dioxin-inducible genes were identified
(e.g. CYP1A1, CYP1A2, CYP1B1 and Tiparp; Table 2) and
there is overlap between our current list of responsive
genes and genes previously reported to be affected by
AHR-ligands in other array experiments [15,17].
To further assess the validity of our array results we
employed real-time RT-PCR to evaluate effects of TCDD
on mRNA levels. Genes were selected for RT-PCR analy-
sis to span a wide range of magnitudes of response (fold-
change in log2: high > 4; medium 2-4; low < 2; or no
response). To this end, both array (Table 2) and RT-PCR
analyses (Figure 4) showed a high magnitude of TCDD-
mediated induction of the prototypical responsive/AHR-
activated gene CYP1A1 [13,32,33]. Further, CYP7A1 and
Chka exhibited medium magnitudes of response to
TCDD in both collectives as evidenced by RT-PCR assays
(Figure 4) as well as, array experiments (Additional File
1). Selenbp1 and Per2 showed low magnitudes of TCDD-
mediated induction in both collectives as evidenced by
array experiments (Additional File 1) and slightly higher
magnitudes of induction by RT-PCR assays (Figure 4).
Elov6 exhibited significant induction in the dioxin-sensi-
tive collective but not in the resistant collective as assayed
both by array (Table 3) and RT-PCR (Figure 4). TCDD
ha d no si gnifi ca n t e ff ect  on m RNA leve ls  f or Klf10 or
Pik3r1 as assayed either by RT-PCR (Figure 4) or by gene
array (Additional File 1).
Analysis of the AHR role in regulation
I t  i s  w e l l - e s t a b l i s h e d  t h a t  m a j o r  t o x i c i t i e s  o f  T C D D
require the AHR [2,4,5,34,35]. To determine if the AHR
was required for the gene to respond to TCDD we com-
pared hepatic mRNA levels for a few genes in Ahr-null
mice (Ahr-/-)  v e r s u s  m i c e  w i t h  w i l d t y p e  A H  r e c e p t o r
(Ahr+/+). Mice were treated with a dose of TCDD equi-
toxic to that in sensitive rats [23] for a comparable time.
As expected, induction of CYP1A1 mRNA was strictly
dependent on the AHR (Figure 5). Suppression of Crip2
mRNA levels also was AHR-dependent (Figure 5). Regu-
lation of Chka and Elovl6 by TCDD appears to be spe-
cies-specific: Chka mRNA was upregulated in rats from
both collectives (Additional File 1 and Figure 4) but was
significantly downregulated in Ahr-null mice and unaf-
fected in wildtype mice (Figure 5); Elovl6 was upregulated
in dioxin-sensitive rats (Table 3 and Figure 4) but Elovl6
was unresponsive to TCDD in both wildtype and Ahr-
null mice (Figure 5). The findings with Chka and Elovl6
reinforce recent reports of substantial differences
between rat and mouse in transcriptional responses to
TCDD [16,23].
Pathway Analysis
To determine if alterations in mRNA abundances caused
by TCDD are functionally coherent, we performed two
Table 1: Extent of overlap in transcript responses to TCDD among dioxin-sensitive and dioxin-resistant rat strains/lines
Sensitive Collective Score
-2 -1 0 1 2
Resistant 
Collective 
Score
-2 51100
-1 14 18 7 0 0
0 26 177 8153 94 17
1 0 0 30 12 26
2 0022 2 0
To evaluate the overlap of significantly (padjusted < 0.01) altered transcripts between the sensitive and resistant collectives we formed a two-
way table. A TCDD-responsive score of -1 (repressed), 0 (unchanged), or +1 (induced) was assigned to each gene in each strain. The sum of 
the scores for the sensitive strains/lines form the columns and the sum of the scores for the resistant strains/lines are the rows. Each value 
corresponds to the number of genes that exhibited a significant response to TCDD treatment. For example, 20 genes are induced in both 
sensitive and both resistant strains/lines, while 5 genes are repressed in both of the sensitive strains/lines and both of the resistant strains/
lines. Of the 8605 genes examined, 452 genes responded in at least 1 strain/line, while 8153 genes did not respond to TCDD in any rat strain/
line.Moffat et al. BMC Genomics 2010, 11:263
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Gene Ontology (GO) analyses. The first used candidate
genes from each rat strain/line to determine the extent of
overlap of pathways between rat strains/lines. We found
that the pathways dysregulated by TCDD were very simi-
lar in the two dioxin-resistant rats, LnA and H/W (Figure
6A) and in the two dioxin-sensitive rats, LnC and L-E
(Figure 6B). Further, there was overlap in pathways
among all strains/lines: 8 GO terms were enriched in all
four strains/lines, while 14 GO terms were specifically
enriched in only the sensitive strains (Figure 6C).
The second analysis used both Type-I and Type-II gene
lists to determine the specific GO terms enriched in each
of the Type-I and Type-II gene lists. This analysis identi-
fied 5 GO terms - mostly relating to cytochrome P450
genes - enriched in the Type-I genes (Table 4). Amongst
the Type-II genes, the analysis identified 14 GO terms
specifically enriched (Table 4). In particular, genes related
to the endoplasmic reticulum were present about 4 times
a s  o f t e n  a s  e x p e c t e d  b y  c h a n c e  a l o n e ,  a s  w e r e  g e n e s
related to lipid metabolism.
Discussion
We performed transcriptional profiling on livers of rats
that are sensitive or resistant to major TCDD toxicities.
Two key findings arise. First, we show significant inter-
strain and inter-species diversity in responses to TCDD.
Second, we identify Type-II genes that may be integral to
the mechanism(s) of hepatotoxicity, wasting and lethality.
Significant diversity of intra-species and inter-species 
responses to TCDD
One startling characteristic of the transcriptional
response to TCDD across the four rat strains/lines are the
dramatic inter-strain differences. Given their substantial
genetic relatedness, including at the AHR locus, it might
be hypothesized that LnA and H/W animals would have
very similar responses, and that LnC would be very simi-
lar to L-E. To the contrary, 68.1% (308 of 452) of dioxin-
responsive genes were altered in one of the four rat
strains/lines. These results clearly demonstrate the
importance of genomic context in regulating mRNA
responses to dioxin-exposure and mirror an analysis of
the basal mRNA levels in these and other rat strains
(Boutros et al. submitted). Interestingly, in rats with the
AHRH/W  genotype, the total number of genes that
respond was reduced relative to rats expressing wildtype
AHR. However, AHRs from rats with the AHRH/W geno-
type have similar affinity for TCDD and ability to bind
AH response elements as wildtype rats [36]. It is conceiv-
able that AHRH/W rats have a reduced ability to recruit
coactivators and interact with transcriptional machinery.
Chromatin immuno-precipitation experiments would be
valuable in testing this hypothesis directly.
When we attempted to study AHR-dependency of the
mRNA changes by comparison with Ahr-/- mice we found
that only 2 of 4 mRNA responses to TCDD, measured by
RT-PCR, could be compared in both rat and mouse mod-
els. This result concords with recent reports of highly
divergent transcriptomic responses to TCDD between rat
and mouse [23], and suggests that combining our intra-
species rat model with inter-species studies may be a
fruitful approach for identifying genes that mediate
TCDD-induced toxicities, especially those toxic
responses that differ between animal species.
Type-II responsive genes whose regulation by TCDD may 
be integral to the mechanism(s) of hepatotoxicity, wasting 
and lethality
In dioxin-sensitive rats, a wasting syndrome commences
within the first few days following a single dose of TCDD
and is characterized by progressive weight loss (eventu-
ally up to 50%) and hypophagia [37-39]. Wasting contrib-
utes to lethality starting 2-3 weeks after TCDD exposure.
Although wasting accompanies death, wasting per se is
not likely to be the sole reason for death since mainte-
nance of body weight by parenteral nutrition does not
prevent mortality [40]. Nevertheless, untreated control
rats, pair-fed at the same caloric intake as rats treated
with lethal TCDD doses, die at much the same time as
their TCDD-exposed partners [41].
Figure 3 Overlap of altered transcripts between rat strains/lines. 
We generated Venn diagrams to visualize the overlap of significantly 
(padjusted < 0.01) altered transcript responses to 100 μg/kg TCDD for 19 
hours between the sensitive and resistant collectives: (A) across the 
sensitive collective, (B) across the resistant collective and (C) across all 
four strains/lines.M
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Table 2: Known dioxin-inducible genes
Resistant Collective Sensitive Collective
H/W LnA L-E LnC
FC log2 padj FC log2 padj FC log2 padj FC log2 padj Gene ID Symbol Full Name
6.3 3.2 × 10-9 5.4 8.2 × 10-8 6.8 2.2 × 10-12 6.2 8.9 × 10-10 25375 Aldh3a1 aldehyde 
dehydrogenase 3 family, 
member A1
6.4 1.3 × 10-4 6.1 1.0 × 10-6 6.6 3.3 × 10-8 6.4 1.8 × 10-9 24296 Cyp1a1 cytochrome P450, 
family 1, subfamily a, 
polypeptide 1
1.2 2.0 × 10-5 1.2 1.6 × 10-5 1.1 1.5 × 10-6 1.1 1.9 × 10-5 24297 Cyp1a2 cytochrome P450, 
family 1, subfamily a, 
polypeptide 2
3.9 6.8 × 10-5 3.5 4.9 × 10-7 5.3 4.4 × 10-6 4.9 7.8 × 10-6 25426 Cyp1b1 cytochrome P450, 
family 1, subfamily b, 
polypeptide 1
1.2 4.4 × 10-3 1.1 1.9 × 10-3 1.9 3.8 × 10-4 1.4 1.9 × 10-3 83619 Nfe2l2 nuclear factor, erythroid 
derived 2, like 2
3.7 3.2 × 10-5 2.5 1.4 × 10-4 2.4 4.9 × 10-5 2.6 4.5 × 10-5 24314 Nqo1 NAD(P)H 
dehydrogenase, 
quinone 1
2.3 1.2 × 10-3 1.8 1.3 × 10-3 2.5 1.6 × 10-4 2.2 1.7 × 10-4 310467 Tiparp TCDD-inducible 
poly(ADP-ribose) 
polymerase
Transcriptional responses after 19-hour TCDD exposure in the four rat strains/lines were identified using Affymetrix RAE230A arrays followed by data pre-processing and statistical testing using 
linear models. Twenty-five Type-I genes (similar response to TCDD in all four strains/lines) were identified. These included several well-established AHR-regulated and dioxin-inducible genes, 
supporting the validity of the array experiments. For each strain/line, the fold-change (FC in log2 space) in mRNA levels between treated and control rats as well as the significance levels are 
presented.M
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Table 3: Type-II gene responses 19 hours after TCDD exposure
Resistant Collective Sensitive Collective
H/W LnA L-E LnC
FC log2 padj FC log2 padj FC log2 padj FC log2 padj Gene ID Symbol Full Name
-0.3 7.3 × 10-2 -0.4 1.1 × 10-2 -0.7 5.7 × 10-4 -0.3 3.0 × 10-3 25368 Adk adenosine kinase
0.4 2.2 × 10-2 0.2 5.6 × 10-2 0.6 6.2 × 10-3 0.4 4.8 × 10-3 305338 Apbb2 amyloid beta (A4) precursor protein-
binding, family B, member 2
-0.4 1.4 × 10-1 -0.3 6.8 × 10-2 -0.8 1.5 × 10-3 -0.5 2.9 × 10-3 25698 Ass1 argininosuccinate synthetase 1
0.3 7.3 × 10-2 0.4 1.1 × 10-2 0.4 7.3 × 10-3 0.4 1.4 × 10-3 116550 Atp5c1 ATP synthase, H+ transporting, 
mitochondrial F1 complex, gamma 
polypeptide 1
-0.9 6.5 × 10-2 -0.6 4.8 × 10-2 -0.9 4.3 × 10-3 -0.8 4.5 × 10-3 64828 B4galnt1 beta-1,4-N-acetyl-galactosaminyl 
transferase 1
0.3 1.6 × 10-1 0.2 6.0 × 10-2 0.6 4.3 × 10-3 0.7 1.5 × 10-3 113948 Bbs2 Bardet-Biedl syndrome 2 homolog (human)
0.3 3.0 × 10-1 0.5 5.7 × 10-2 0.5 1.0 × 10-3 0.6 2.2 × 10-3 292027 Cfdp1 craniofacial development protein 1
-0.2 2.3 × 10-1 -0.3 7.1 × 10-2 -0.6 1.0 × 10-3 -0.6 1.5 × 10-3 85251 Col18a1 collagen, type XVIII, alpha 1
-0.3 3.2 × 10-1 -0.5 6.6 × 10-2 -0.9 1.7 × 10-4 -0.4 9.4 × 10-3 266682 Cyp3a2 cytochrome P450, family 3, subfamily a, 
polypeptide 2
-0.4 2.8 × 10-1 -0.5 3.3 × 10-2 -0.9 7.8 × 10-5 -0.5 2.2 × 10-3 286904 Cyp4f4 cytochrome P450, family 4, subfamily f, 
polypeptide 4
0.4 1.2 × 10-2 0.2 5.0 × 10-2 0.4 1.2 × 10-3 0.4 3.5 × 10-3 362912 Derl1 Der1-like domain family, member 1
0.6 6.6 × 10-2 0.3 2.3 × 10-2 0.6 1.7 × 10-3 0.6 6.5 × 10-4 691956 Derl2 Der1-like domain family, member 2
-0.4 1.5 × 10-1 -0.3 1.0 × 10-1 -0.4 5.9 × 10-3 -0.5 9.7 × 10-3 25313 Egf epidermal growth factor
0.3 6.3 × 10-1 1.1 2.0 × 10-1 1.2 3.3 × 10-4 0.6 9.8 × 10-3 171402 Elovl6 ELOVL family member 6, elongation of long 
chain fatty acids (yeast)
-0.3 2.9 × 10-1 -0.3 7.2 × 10-2 -0.7 1.0 × 10-3 -0.5 9.4 × 10-3 29580 Fdft1 farnesyl diphosphate farnesyl transferase 1
-0.3 3.7 × 10-1 -0.3 4.3 × 10-2 -0.7 4.2 × 10-4 -0.4 4.1 × 10-3 297029 Gstk1 glutathione S-transferase kappa 1
-0.5 9.3 × 10-2 -0.2 1.8 × 10-1 -0.7 6.9 × 10-3 -0.4 3.0 × 10-3 81869 Gstm7 glutathione S-transferase, mu 7
-1.3 7.2 × 10-3 -1.0 1.1 × 10-3 -1.1 3.4 × 10-2 -1.2 1.2 × 10-2 85255 Hacl1 2-hydroxyacyl-CoA lyase 1
-0.2 6.3 × 10-1 -0.3 1.8 × 10-1 -0.7 6.5 × 10-4 -0.7 2.2 × 10-3 24439 Hagh hydroxyacyl glutathione hydrolase
-0.6 2.5 × 10-2 -0.2 2.1 × 10-1 -0.6 2.7 × 10-3 -0.7 4.7 × 10-3 25116 Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1
0.5 1.5 × 10-1 0.3 1.1 × 10-1 0.9 1.0 × 10-3 0.6 4.8 × 10-3 84013 Hsd17b12 hydroxysteroid (17-beta) dehydrogenase 12M
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1.4 5.1 × 10-3 0.5 3.9 × 10-3 0.7 4.3 × 10-2 0.9 1.5 × 10-2 25663 Il1r1 interleukin 1 receptor, type I
-0.6 3.7 × 10-2 -0.3 1.8 × 10-1 -0.7 3.8 × 10-3 -0.8 6.1 × 10-4 690745 LOC690745 MOCO sulphurase C-terminal domain 
containing-like
0.2 8.5 × 10-1 -0.5 4.2 × 10-2 -0.8 8.5 × 10-4 -0.5 4.8 × 10-3 497794 Mug1 murinoglobulin 1
-0.4 8.6 × 10-2 -0.4 4.1 × 10-2 -0.6 3.6 × 10-3 -0.6 8.6 × 10-3 29227 Nfib nuclear factor I/B
-0.5 9.3 × 10-2 -0.6 3.2 × 10-2 -1.2 1.0 × 10-3 -0.5 1.4 × 10-3 680451 Nrbp2 nuclear receptor binding protein 2
-0.2 6.1 × 10-1 -0.4 1.0 × 10-2 -0.6 2.5 × 10-4 -0.5 3.4 × 10-3 94267 Nudt4 nudix (nucleoside diphosphate linked 
moiety X)-type motif 4
1.0 1.6 × 10-2 0.7 4.2 × 10-2 0.7 4.6 × 10-3 1.2 1.9 × 10-5 171564 Pbld phenazine biosynthesis-like protein domain 
containing
0.4 4.5 × 10-2 0.3 4.2 × 10-2 0.4 7.6 × 10-3 0.4 1.5 × 10-3 308061 Pdcd6 programmed cell death 6
0.7 5.1 × 10-3 0.7 2.0 × 10-4 0.4 1.1 × 10-1 0.7 1.3 × 10-2 114209 Phyh phytanoyl-CoA 2-hydroxylase
0.6 1.6 × 10-2 0.4 5.2 × 10-2 0.5 2.7 × 10-3 0.8 7.7 × 10-5 64390 Prpsap1 phosphoribosyl pyrophosphate synthetase-
associated protein 1
-0.3 3.3 × 10-1 -0.4 7.0 × 10-2 -0.6 4.3 × 10-3 -0.5 2.9 × 10-3 315655 Rdx radixin
-0.2 1.2 × 10-1 -0.4 1.5 × 10-2 -0.6 5.0 × 10-3 -0.5 1.3 × 10-3 363160 RGD1311563 similar to Oligosaccharyl transferase 3 
CG7748-PA
0.1 3.1 × 10-1 0.2 1.1 × 10-1 1.4 7.3 × 10-3 0.7 4.1 × 10-4 315611 Scn4b sodium channel, type IV, beta
-0.3 3.7 × 10-1 -0.6 2.9 × 10-2 -1.2 6.8 × 10-4 -0.9 5.1 × 10-3 25216 Sdc1 syndecan 1
0.4 8.4 × 10-2 0.4 2.3 × 10-2 0.5 4.3 × 10-3 0.6 7.9 × 10-3 680891 Sf3b5 splicing factor 3b, subunit 5
-0.2 5.9 × 10-1 -0.3 3.5 × 10-2 -0.5 2.5 × 10-4 -0.4 2.6 × 10-3 81536 Sgpp1 sphingosine-1-phosphate phosphatase 1
-0.8 2.1 × 10-2 -0.6 5.0 × 10-2 -0.7 4.2 × 10-4 -0.7 2.0 × 10-3 79111 Slc27a5 solute carrier family 27 (fatty acid 
transporter), member 5
0.6 2.1 × 10-2 0.4 1.7 × 10-2 0.5 4.4 × 10-3 0.7 3.7 × 10-4 500707 Tc2n tandem C2 domains, nuclear
0.2 4.4 × 10-1 0.3 5.0 × 10-2 0.3 7.0 × 10-3 0.5 3.0 × 10-3 367909 Tceal8 transcription elongation factor A (SII)-like 8
-0.2 3.7 × 10-1 -0.3 8.3 × 10-2 -0.5 3.3 × 10-3 -0.4 3.4 × 10-3 170907 Tpo1 developmentally regulated protein TPO1
0.7 2.2 × 10-2 0.3 7.4 × 10-2 0.6 7.5 × 10-3 0.6 4.1 × 10-3 362890 Tspan31 tetraspanin 31
-0.2 3.8 × 10-1 -0.1 7.8 × 10-1 -0.4 6.3 × 10-3 -0.4 3.4 × 10-3 362696 Ttc7 tetratricopeptide repeat domain 7
-0.1 7.8 × 10-1 -0.3 6.2 × 10-2 -0.5 5.4 × 10-3 -0.5 4.5 × 10-3 363869 Ubl3 ubiquitin-like 3
-0.9 1.5 × 10-1 -0.5 2.9 × 10-1 -0.9 1.5 × 10-4 -1.1 1.3 × 10-3 117522 Xpnpep2 X-prolyl aminopeptidase (aminopeptidase 
P) 2, membrane-bound
0.3 4.6 × 10-2 0.4 1.2 × 10-2 0.6 1.3 × 10-3 0.7 4.3 × 10-3 360389 Zfp422 zinc finger protein 422
Transcriptional responses after 19 hours TCDD exposure in the four rat strains/lines were identified using Affymetrix RAE230A arrays followed by data pre-processing and statistical testing using 
linear models. Type-II genes were identified as those where both strains/lines in one collective showed statistically significant responses to TCDD (padjusted < 0.01) in the same direction, while both 
strains/lines in the other collective showed no response (padjusted > 0.01). For each strain/line, the fold-change (FC in log2 space) in mRNA levels between treated and control rats as well as the 
significance levels are presented. Genes are sorted alphabetically by gene symbol.
Table 3: Type-II gene responses 19 hours after TCDD exposure (Continued)Moffat et al. BMC Genomics 2010, 11:263
http://www.biomedcentral.com/1471-2164/11/263
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Figure 4 Gene responses to TCDD exposure in livers of dioxin-resistant and dioxin-sensitive rats: measurement of selected mRNA levels by 
real-time RT-PCR. Hepatic RNA was prepared from male adult TCDD-sensitive rats (L-E and LnC) and TCDD-resistant rats (H/W and LnA) after 19-hour 
treatment with a single dose of 100 μg/kg TCDD or corn-oil vehicle control by gavage. mRNA levels were measured by real-time RT-PCR and normal-
ized as described in Materials & Methods. For each gene, the mRNA level that was highest for any strain/line or treatment was set at 100% and all other 
mRNA levels for that gene are shown as a percentage of that maximal level. All results plotted represent the mean ± standard deviation of four rats. 
Asterisks indicate significant differences in mRNA levels between control and TCDD-treated rats (t-test; two-tailed, unequal variance, * p < 0.05, ** p < 
0.01, *** p < 0.001). Note: levels of CYP1A1 mRNA in control animals were below detection limits (ND).Moffat et al. BMC Genomics 2010, 11:263
http://www.biomedcentral.com/1471-2164/11/263
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The cause of TCDD-induced wasting and ultimate
death as well as the key target tissue(s) remain elusive.
Since TCDD causes extensive hepatotoxicity in TCDD-
sensitive rats (but not in the TCDD-resistant strains), it is
reasonable that examination of mechanisms which pro-
duce hepatotoxicity may provide clues to mechanisms of
wasting and lethality. To this end, we identified 46 Type-
II hepatic genes whose TCDD-responsiveness differed
between TCDD-resistant and TCDD-sensitive rats. Path-
way analysis indicated that these genes are mainly
involved in lipid-metabolism, cellular membrane func-
tion and energy metabolism (Table 4). These Type-II
Figure 5 Gene responses to TCDD exposure in livers of Ahr-null versus wildtype mice: measurement of selected mRNA levels by real-time 
RT-PCR. Hepatic RNA was prepared, as described in Materials and Methods, from male adult Ahr-null mice (Ahr-/-) and wildtype C57BL/6J mice (Ahr+/
+) after treatment with a single dose of 1000 μg/kg TCDD or corn oil vehicle for 19 hours. There were 3 TCDD-treated and 3 control mice in the Ahr-
null groups and 4 TCDD-treated and 4 control mice in the wildtype groups. Levels for selected mRNAs used in the RT-PCR array validity experiments 
in rats were measured by real-time RT-PCR and normalized to Actb in this mouse model [60]. For each gene, the highest mRNA level across all exper-
iments was set at 100% and all other mRNA levels for that gene are shown as a percentage of that maximal level. Error bars represent standard devi-
ation of the mean. Asterisks indicate differences in mRNA levels (ANOVA followed by Bonferroni post hoc tests, * p < 0.05, *** p < 0.001). Note that for 
CYP1A1 the mRNA level in control animals or in TCDD-treated Ahr-/- mice or control Ahr-/- mice is below the detection limit of the assay; thus there are 
no bars visible for these groups in this plot (ND).Moffat et al. BMC Genomics 2010, 11:263
http://www.biomedcentral.com/1471-2164/11/263
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genes potentially explain why there are greater manifesta-
tions of hepatotoxicity in sensitive rats than in resistant
rats; for example, a dramatic accumulation of fatty acids
(steatosis) and initial liver hypertrophy which switches to
atrophy ~1 week later (refer to [24] for exhaustive list of
hepatotoxic responses). Pohjanvirta et al. [24], in bio-
chemical studies, found that exposure of sensitive rats to
TCDD led to steatosis, hypertrophy, liver failure, wasting
and eventual death, possibly as the consequence of derail-
ment of energy metabolism due to alterations of (i) lipid
homeostasis, (ii) protein metabolism and/or (iii) ATP
production/utilization.
(i) Alteration of lipid homeostasis
In sensitive rats only, we previously observed steatosis
with the accumulated fatty acids probably originating
from redistribution of peripheral fat deposits to liver
rather than from increased lipid synthesis within the liver
[42]. This is consistent with our current transcriptomic
study in which transcripts related to lipid synthesis were
not increased. TCDD-induced suppression of hepatic
lipid lipogenesis previously has been reported [16,17,43].
Pathway analysis indicated that genes involved in the
lipid metabolism process were enriched in the Type-II
gene list. Of particular interest was the decreased expres-
sion of Hsd11b1 and Slc27a5 only in sensitive rats.
Hsd11b1 functions in steroid metabolism and colocalizes
with the glucocorticoid receptor where it acts as a local
amplifier of corticoid responses including the regulation
of fuel metabolism during starvation and stress [44,45].
Hsd11b1 deficiencies in rodents increase energy expendi-
ture, decrease weight gain with chronic high fat feeding,
increase weight loss, increase hepatic lipid oxidation
while decreasing lipolysis in adipose tissue and display
many metabolic deficiencies [45,46]. Slc27a5 encodes a
transporter of long-chain fatty acids into the liver where
it is exclusively expressed. Its deletion results in increased
de novo biosynthesis of long-chain fatty acids in liver due
to inhibited uptake of them. Interestingly, in knockout
mice, feed intake is depressed, energy expenditure
increased and weight gain suppressed [47,48]. While fur-
ther study of these genes is warranted, genes that alter
lipid homeostasis may be important in hepatotoxicity and
could be involved in pro-death pathways in sensitive rats
exposed to TCDD.
(ii) Altered protein metabolism
In the short term, protein catabolism can be a beneficial
response to provide amino acids for energy and mainte-
nance of obligatory functions. However, sustained pro-
tein catabolism eventually leads to wasting and mortality.
Our current study found that TCDD increased expres-
sion of genes that facilitate protein breakdown (Derl1,
Derl2 and Mug1) but also decreased the expression of
Ass1, the key enzyme in the urea cycle. Deficiencies in
Ass1 may disrupt the urea cycle resulting in increased
accumulation of amino acids, highly toxic ammonia and
other toxic byproducts. TCDD previously has been
shown to decrease the expression of the Ass1 gene after
24 hour exposure [17]. Increased protein breakdown and
deficiencies in the urea cycle are consistent with previous
reports of elevated plasma levels of most amino acids and
decreased plasma urea in sensitive rats but not in resis-
tant rats 6 days after TCDD exposure [49]. In addition,
alteration of the balance between protein synthesis versus
protein degradation is a key mechanism in switching
hepatocytes from hypertrophy to atrophy, as observed in
sensitive rats ~1 week after TCDD exposure [24] and
reported for other wasting diseases (e.g. diabetes and
cancer cachexia) [50]. Thus, specific genes involved in
protein homeostasis are likely important in TCDD-medi-
ated pro-survival pathways.
(iii) Impaired ATP production/utilization
Derailment of energy metabolism due to impaired ATP
production or utilization potentially contributes to mani-
festations of major TCDD toxicities. After TCDD expo-
sure in sensitive rats, compensatory mechanisms may
attempt to increase energy for metabolism by increasing
expression of the Atp5c1 gene that resides within the ATP
Figure 6 Overlap of functional terms between rat strains/lines. 
Gene Ontology (GO) analysis was used to determine if different com-
binations of strains/lines led to alterations in mRNA levels for function-
ally coherent groups of genes. The gene-lists for each of the four 
strains/lines were tested for enrichment of each GO category repre-
sented on the RAE230A array. False-discovery rates were calculated 
with 1000 permutations of the dataset using the High-Throughput 
GoMiner software and a threshold of 5% FDR was applied. The vast ma-
jority of GO terms enriched in both the resistant (A) and the sensitive 
(B) strains/lines overlap. A four-way overlap of all strains/lines shows 
significant overlap, but also some strain-specific responses (C).Moffat et al. BMC Genomics 2010, 11:263
http://www.biomedcentral.com/1471-2164/11/263
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Table 4: Enrichment of functional terms within Type-I response and Type-II response gene lists from rat strains/lines
Type-I Type-II
GO ID Enrichment FDR Enrichment FDR Functional term
GO:0042175 2.20 1.00 2.68 0.00 nuclear envelope-endoplasmic reticulum 
network
GO:0005789 2.23 1.00 2.71 0.00 endoplasmic reticulum membrane
GO:0044432 2.06 1.00 2.54 0.00 endoplasmic reticulum part
GO:0044255 1.44 1.00 2.21 0.01 cellular lipid metabolic process
GO:0006629 1.28 1.00 2.05 0.01 lipid metabolic process
GO:0005783 1.63 1.00 1.99 0.01 endoplasmic reticulum
GO:0012505 1.07 1.00 1.84 0.02 endomembrane system
GO:0031090 0.55 1.00 1.57 0.02 organelle membrane
GO:0031301 NA 1.00 3.70 0.02 integral to organelle membrane
GO:0031300 NA 1.00 3.57 0.02 intrinsic to organelle membrane
GO:0030176 NA 1.00 4.46 0.02 integral to endoplasmic reticulum 
membrane
GO:0031227 NA 1.00 4.25 0.03 intrinsic to endoplasmic reticulum 
membrane
GO:0003824 0.86 0.48 0.82 0.05 catalytic activity
GO:0016491 2.69 0.02 1.94 0.03 oxidoreductase activity
GO:0016712 5.06 0.01 3.37 0.28 oxidoreductase activity acting on paired 
donors with incorporation or reduction of 
molecular oxygen reduced flavin or 
flavoprotein as one donor and 
incorporation of one atom of oxygen
GO:0020037 4.04 0.01 1.93 0.72 heme binding
GO:0046906 4.04 0.01 1.93 0.72 tetrapyrrole binding
GO:0004497 4.42 0.02 2.31 0.59 monooxygenase activity
Gene Ontology (GO) analysis was used to determine if genes exhibiting Type-I (dioxin-responsive across both collectives) or Type-II (dioxin-
responsive in only one collective) character were functionally coherent. Lists of Type-I and Type-II genes generated as described in the Results 
were tested for enrichment of each GO category represented on the RAE230A array. False-discovery rates (FDR) were calculated with 1000 
permutations of the dataset using the High-Throughput GoMiner software, bolding highlights those terms with a FDR <5%. Enrichment 
values are expressed in log2-space (i.e. a value of 3.0 indicates an 8-fold enrichment). Note that GO:0016491 (oxidoreductase activity) is 
enriched in both the Type-I and Type-II gene lists.
synthesis pathway and is down-regulated in obese sub-
jects [51]. However, TCDD decreased expression levels of
Adk which catalyzes the inter-conversion of adenine
nucleotides, and plays an important role in cellular
energy homeostasis (2 ADP ￿ ATP + AMP); this down-
regulation may impair use of ATP as an energy source in
sensitive rats. Specifically, Adk impairment leads to defi-
ciencies in adenosine nucleotides, including ATP, likely
leading to reduced mitochondrial metabolic capacity and
impairment of lipid metabolism critical for energy pro-
duction [52]. Moreover, Adk-deficient mice display
hepatic steatosis within 4 days and die within 14 days
with fatty liver [52]. Thus, deficiencies in adenosine
metabolism are powerful contributors to development of
hepatic steatosis and development of lethal fatty liver,
processes that are also provoked by TCDD in sensitive
rats.
In dioxin-resistant rats, where TCDD does not cause
severe hepatotoxicity, wasting or death, there was no
alteration of mRNA levels for genes which might derail
energy metabolism due to alterations of in the homeosta-
sis of lipids, protein metabolism or ATP production/utili-
zation. Only three genes responded to TCDD in the
resistant collective but not in the sensitive collective. Two
of these three genes function in lipid metabolism: the
expression of Phyh was increased while that of Hacl1 was
decreased. The third gene Il1r1, whose levels were
increased by TCDD, is a receptor whose responsiveness
regulates several biological functions, including adaptive
and innate immunity, control of programmed cell deathMoffat et al. BMC Genomics 2010, 11:263
http://www.biomedcentral.com/1471-2164/11/263
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and stress response [53]. The consequences of altered
regulation of these genes in mediating potential pro-sur-
vival pathways in response to TCDD warrants further
investigation.
Conclusion
The mechanisms of dioxin-induced toxicities remain elu-
sive but our transcriptomic approach in an in vivo rat
model where there are major phenotypic differences in
the toxic response is providing clues to the early events
that may trigger toxicity. Compelling evidence shows that
the transcriptional activity of the AHR is essential for tox-
icity. Because altered transcription is central to TCDD
toxicity, our group and others have profiled changes of
mRNA abundance resulting from exposure to TCDD in
several model systems. The results are remarkable:
TCDD induces wide-spread alterations in mRNA abun-
dance, but only a very small fraction of these changes are
conserved between mouse or rat and, as demonstrated
here, within different rat strains. Only 31.9% of dioxin-
responsive genes are altered in more than one of the four
rat strains/lines.
This diversity of transcriptional responses makes it
challenging to identify specific genes responsible for
lethality and other major forms of dioxin toxicity. Our
results suggest that hepatic toxicity probably is not
caused by dysregulation of a single critical gene. Rather,
pathways such as lipid metabolism or energy metabolism
may be derailed by altered transcription of multiple
genes, possibly under coordinate control of the AHR with
participation of other regulatory factors. Pathways and
individual genes highlighted here are worthy candidates
for further mechanistic studies to test their role in medi-
ating or protecting from major dioxin toxicities.
Methods
Animals and Treatments for Rat Model
We studied two dioxin-sensitive rat strains/lines express-
ing wildtype AHR: Long-Evans (Turku/AB) (L-E) and
Line-C (LnC). We also studied two dioxin-resistant rat
strains/lines expressing the Han/Wistar variant AHR:
Han/Wistar (Kuopio) (H/W) and Line-A (LnA) [25]. All
animals were males 10-12 weeks of age from breeding
colonies of the National Institute for Health and Welfare,
Kuopio, Finland. They were housed in groups of 4 (an
entire treatment group per cage) in suspended stainless-
steel wire-mesh cages with pelleted R36 feed (Lactamin,
Stockholm, Sweden) and tap water available ad libitum.
The temperature in the animal room was 21 ± 1°C, rela-
tive humidity 50 ± 10%, and a 12 hour-light/12 hour-dark
cycle. Study plans were approved by the Animal Experi-
ment Committee of the University of Kuopio and the Pro-
vincial Government of Eastern Finland. There were four
rats per treatment group. Liver was harvested between
8:30 and 11:00 from rats treated by gavage with a single
100 μg/kg dose of TCDD or corn oil vehicle 19 hours pre-
viously. The single dose of 100 μg/kg TCDD produces
hepatotoxicity, wasting and death in sensitive rats but not
in resistant rats.
Animals and Treatment for Mouse Model
Liver tissues were from mice in which we previously
mapped AHR-dependent and dioxin-dependent gene
batteries by transcriptomic analysis [20]. Briefly, male
Ahr-null (Ahr-/-) mice in a C57BL/6J background (10
weeks old) and C57BL/6 mice carrying wildtype (Ahr+/+)
(15 weeks old) were given a single dose of 1000 μg/kg
TCDD or corn oil vehicle by gavage. Liver was harvested
19 hours after treatment. The single dose of TCDD is
lethal to wild-type but not Ahr-null mice and is equitoxic
to that given to sensitive rats. We tested 3 TCDD-treated
and 3 control mice in the Ahr-/- groups and 4 TCDD-
treated and 4 control mice in the Ahr+/+ groups.
RNA Extraction
Total RNA was extracted using Qiagen RNeasy kits
according to the manufacturer's instructions (Qiagen,
Mississauga, Canada). Total RNA yield was quantified by
UV spectrophotometry and RNA integrity was verified
using an Agilent 2100 BioAnalyzer (Agilent Technolo-
gies, Santa Clara, CA).
Microarray analysis
Sample labeling and hybridization to Affymetrix
RAE230A GeneChips® were performed by The Centre for
Applied Genomics (Toronto, Canada) according to the
manufacturer's protocols. At each condition four separate
animals were profiled, each on an individual RAE230A
microarray. Raw array data were examined for spatial and
distributional heterogeneity and differential RNA degra-
dation; no arrays were excluded. Array data were loaded
into the R statistical environment (v2.9.2) using the affy
package (v1.22.1) of the BioConductor open-source
library [54]. Array data were pre-processed with the
RMA algorithm [55]. Raw and pre-processed array data
are available in the Gene Expression Omnibus repository
at NCBI (accession GSE10083). An alternative CDF pack-
age was used to ensure each ProbeSet was mapped to a
single unique Entrez Gene ID (rae230arnentrezgcdf
v12.0.0) [56].
Statistical analysis of array data
The experimental design employed independent pair-
wise analyses between treated and control animals for
each strain/line (Figure 1). Following quality control and
pre-processing of the microarray data, we performed a
general linear modeling analysis. For each gene and each
strain we determined the magnitude of differential signal
intensity between TCDD-exposed and vehicle-treatedMoffat et al. BMC Genomics 2010, 11:263
http://www.biomedcentral.com/1471-2164/11/263
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animals. Gene-lists were derived separately for each
strain using the limma package (v2.18.3) in the R statisti-
cal environment (v2.9.2) with a condition-specific design
matrix and within-strain pair-wise contrasts. An empiri-
cal Bayes moderation of the standard error [57] and false-
discovery rate control of multiple-testing were applied
[58]. A significance threshold of padjusted  < 0.01 was
applied to each contrast. We then scored each gene using
a scheme described previously [30]. Briefly, each gene
was classified as unaltered (Score: 0), statistically signifi-
cantly repressed by TCDD (Score: -1), or statistically sig-
nificantly induced by TCDD (Score: +1) in each strain,
and these strain-wise scores were summed.
Unsupervised machine-learning was performed using
divisive hierarchical clustering with complete linkage in
the R statistical environment (v2.9.2) using the cluster
package (v1.12.1). Pearson's correlation was used as a
similarity metric and within-row scaling was performed.
Venn diagrams were produced using custom R code. R
visualizations employed the lattice (v0.17-26) and lattice-
Extra (v0.6-3) packages.
Functional characterization of responsive genes
To determine if genes perturbed by TCDD are enriched
for specific Gene Ontology (GO) terms, we first identi-
fied groups of genes dysregulated by TCDD within each
strain/line (padjusted < 0.01). Then GO terms enriched in
these groups were identified using the GoMiner tool [59].
False-discovery rates (FDRs) were estimated using 1000
permutations. Rat-specific annotations were used. GO
terms with false-discovery rates below 5% were included
in subsequent analyses.
mRNA quantitation by Real-Time RT-PCR
Total RNA (2 μg) was reverse-transcribed into cDNA
using oligo-dT primer p(dT)15 (Roche Applied Science,
Laval, QC, Canada) and Superscript II RNA polymerase
according to the manufacturer's instructions (Invitrogen,
Carlsbad, CA). Real-time PCR was performed using in-
house designed primers (with 5' fluorogenic probes, as
described previously [30]) or Applied Biosystems gene
expression assays, as described by the manufacturer
(Applied Biosystems, Forest City, CA). Primer/probe
sequences are in Additional File 2.
Normalized expression was calculated as 2−ΔΔCt, where
Ct is the threshold cycle for detecting fluorescence. PCR
amplification efficiency was determined from a 10-fold
serial dilution of a cDNA pool; efficiency ranged from 90-
110% for all genes. Data were normalized to either Actb
or Gapdh, genes we previously showed to be suitable as
normalization standards for dioxin studies [60]. In the rat
model, significant differences in mRNA levels were deter-
mined using t-tests (two-tailed, unequal variance). Signif-
icant differences in mRNA levels in the Ahr-null mouse
model were identified using analysis of variance
(ANOVA) with Bonferroni post hoc tests (GraphPad ver-
sion 4.0).
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